SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-23-096077
Filing Date
2023-12-15
Accepted
2023-12-15 16:06:12
Documents
14
Period of Report
2023-12-11
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea190135-8k_tffpharm.htm   iXBRL 8-K 27662
2 PRESS RELEASE DATED DECEMBER 13, 2023 ANNOUNCING THE APPOINTMENT OF THOMAS KING ea190135ex99-1_tffpharm.htm EX-99.1 12242
3 GRAPHIC ex99-1_001.jpg GRAPHIC 3561
  Complete submission text file 0001213900-23-096077.txt   225349

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE tffp-20231211.xsd EX-101.SCH 3018
5 XBRL LABEL FILE tffp-20231211_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE tffp-20231211_pre.xml EX-101.PRE 22361
8 EXTRACTED XBRL INSTANCE DOCUMENT ea190135-8k_tffpharm_htm.xml XML 3416
Mailing Address 2600 VIA FORTUNA, SUITE 360 AUSTIN TX 78746
Business Address 2600 VIA FORTUNA, SUITE 360 AUSTIN TX 78746 737-802-1973
TFF Pharmaceuticals, Inc. (Filer) CIK: 0001733413 (see all company filings)

IRS No.: 824344737 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39102 | Film No.: 231490317
SIC: 2834 Pharmaceutical Preparations